Colombo Diego, Compostella Federica, Ronchetti Fiamma, Reza-Elahi Shahrzad, Scala Antonio, Toma Lucio, Aoi Wataru, Kuchide Masashi, Takayasu Junko, Tokuda Harukuni, Nishino Hoyoku
Dipartimento di Chimica e Biochimica Medica, Università di Milano, Via Saldini 50, 20133 Milan, Italy.
Cancer Lett. 2002 Dec 1;186(1):37-41. doi: 10.1016/s0304-3835(02)00336-1.
Nine new synthetic compounds, structurally related to the most active glycoglycerolipid analogues carrying a hexanoyl chain, were tested for their anti-tumor-promoting activity using a short-term in vitro assay for Epstein-Barr virus (EBV) activation. All these compounds, in which the ester function is replaced by different metabolically more stable groups, were almost as active as their ester reference compounds in inhibiting the EBV activation promoted by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Two of these, devoid of any functionality on the lipophilic chain, when tested in an in vivo two-stage carcinogenesis test, exhibited marked inhibitory effects on mouse skin tumor promotion.
